Diarrhea Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Diarrhea Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diarrhea - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Diarrhea (Gastrointestinal) pipeline landscape.

Diarrhea is a contagious gastrointestinal infection occurring mostly due to unhygienic conditions. Diarrhea may be related to a viral or bacterial infection and is sometimes the result of food poisoning. Symptoms include nausea, abdominal pain, cramping, bloating, dehydration, fever, bloody stools, frequent urge to evacuate the bowels and incontinence. Treatment includes medication and healthy lifestyle.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diarrhea - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Diarrhea (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diarrhea (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Diarrhea and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 11, 6, 1, 18 and 5 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 3 and 5 molecules, respectively.

Diarrhea (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Diarrhea (Gastrointestinal).
• The pipeline guide reviews pipeline therapeutics for Diarrhea (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Diarrhea (Gastrointestinal) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Diarrhea (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Diarrhea (Gastrointestinal)

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Diarrhea (Gastrointestinal).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Diarrhea (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned
Companies Mentioned

AbbVie Inc
Boston Pharmaceuticals Inc
Chongqing Zhifei Biological Products Co Ltd
Cosmo Pharmaceuticals NV
DiscoveryBiomed Inc
Emergent BioSolutions Inc
First Wave BioPharma Inc
Glycosyn LLC
Hilleman Laboratories Pvt Ltd
Immuron Ltd
Jaguar Health Inc
Lumen Bioscience Inc
Microba Life Sciences Ltd
MyBiotics Pharma Ltd
Napo Pharmaceuticals Inc
NGM Biopharmaceuticals Inc
Nippon Shinyaku Co Ltd
Nuvara Therapeutics LLC
OnQuality Pharmaceuticals LLC
Orphomed Inc
Prokarium Ltd
Protagonist Therapeutics Inc
RaQualia Pharma Inc
Rebiotix Inc
RedHill Biopharma Ltd
RxBio Inc
Scandinavian Biopharma Holding AB
Synthetic Biologics Inc
Syntiron LLC
TenNor Therapeutics Ltd
Vanda Pharmaceuticals Inc
Vanessa Biotech
Wuhan Institute of Biological Products Co Ltd
Yisheng Biopharma Co Ltd
Zhiyi Pharmaceuticals Inc